ABOUTQUANTA VISION
Preventive medicine focuses on identifying risks early to stop diseases before they develop. Nearly half of global deaths—from cardiovascular to addiction-related disorders—are considered preventable. Early prevention not only saves lives but also reduces the burden on families and healthcare systems.
Founded in 2020, Quanta Vision integrates optical sensing, AI, medical science, and psychology to create intelligent tools for preventive healthcare across physiological, psychological, pharmaceutical, microbial, and clinical applications.
Our solutions deliver fast, accurate, and safe mind–body assessments, offering real-time diagnostics for institutions and individuals—even at home. With early prevention and timely insight, we stay true to our mission: bringing light to people’s lives.
About SmarTest R&D Center
SmarTest R&D Center was founded in 2023 by CIBI Lab at National Taiwan University, led by Professor Chou, Cheng-Ying, in collaboration with Quanta Vision. The Center builds on the Saliva-Based Drug Screening Project initiated in 2013. By integrating AI, biometrics, optical design, and data analytics, and working closely with judicial, medical, and addiction treatment partners, SmarTest develops high-accuracy, rapid saliva-based screening solutions.
Supported by the National Science and Technology Council and recognized in 2020 by Academia Sinica’s Taiwan Advanced Instrument Program, the technology has been successfully commercialized.
SmarTest is dedicated to advancing fast, precise, and accessible biosensing tools for early prevention, precision detection, and whole-person recovery, enhancing public and workplace safety.